Our Formulation portfolio focuses on evidence-backed Phytopharmaceuticals for present unmet clinical needs. One of the R&D priority area is annihilation of Vector Borne Diseases for which we have been funded through BIRAC (Govt. of India). The R&D pipeline has a few nano-technology formulations aimed at malaria eradication by 2030. We are also developing a highly potent anti-viral agent with immunomodulatory properties under the brand name Punikavir® which has been found suitable for a therapeutic intervention against enveloped viruses like Influenza-A, HIV, RSV, SARS-CoV-2 and Dengue . The portfolio includes functional nutraceuticals, proven to slow down and possibly retard onset of certain chronic diseases and as a potential healthy ageing supplement.